Daily smoking intensity increases lung cancer risk through sphingomyelin and phosphatidylcholine: An in-silico using European population and Mendelian randomization
Open Access
- 15 May 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (20) , e48844
Abstract
Lung cancer is a leading cause of morbidity and mortality worldwide, with smoking as a major risk factor. This study investigated the causal relationship between smoking intensity, plasma lipid phenotypes, and lung cancer risk using Mendelian randomization (MR) analysis. Bidirectional MR analysis examined daily cigarette consumption’s impact on non-small cell carcinoma, not otherwise specified (NOS), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and small cell lung cancer (SCLC). Associations between smoking and 179 plasma lipid phenotypes were explored, followed by analysis of lipid groups’ causal links to lung cancer subtypes. Mediation MR estimated the mediation proportion. Smoking intensity showed a significant positive correlation with all lung cancer subtypes (non-small cell carcinoma, not otherwise specified (NOS) [NSCLC-NOS]: odds ratio [OR] = 2.31, 95% confidence interval [CI] = 1.30–4.10; LUAD: OR = 2.99, 95% CI = 1.47–6.10; LUSC: OR = 3.69, 95% CI = 1.39–9.80; SCLC: OR = 3.66, 95% CI = 1.06–12.56). Increased smoking was linked to lower levels of 3 phosphatidylcholine (PC) and higher levels of 2 sphingomyelin (SM) molecules. Bayesian weighted MR revealed 41 plasma lipid phenotypes significantly affected lung cancer risk. PC (16:0_0:0) and SM (d36:2) mediated 1.79% and 3.27% of the risk for NSCLC-NOS, respectively, while SM (d42:2) mediated 2.72% of the risk for SCLC. The study established a causal relationship between daily smoking intensity and the risk of both NSCLC and SCLC, mediated by changes in specific plasma lipid phenotypes. This highlights the critical role of lipid metabolism in smoking-related lung cancer. Understanding the lipid metabolic pathways involved in smoking-induced lung cancer could aid in the development of targeted interventions, potentially reducing the elevated cancer risk associated with increased smoking intensity.Keywords
This publication has 36 references indexed in Scilit:
- Role of ceramide/sphingomyelin (SM) balance regulated through “SM cycle” in cancerCellular Signalling, 2021
- Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian RandomizationJAMA, 2021
- Trans‐omic profiling between clinical phenoms and lipidomes among patients with different subtypes of lung cancerClinical and Translational Medicine, 2020
- A comparison of robust Mendelian randomization methods using summary dataGenetic Epidemiology, 2020
- Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung CancerChest, 2019
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016
- Non‐small cell lung cancer is characterized by dramatic changes in phospholipid profilesInternational Journal of Cancer, 2015
- Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracyJournal of Clinical Epidemiology, 2015
- Cigarette smoking and lung cancer: chemical mechanisms and approaches to preventionThe Lancet Oncology, 2002